MGIM
FATE icon

M&G Investment Management’s Fate Therapeutics FATE Stock Holding History

M&G Investment Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-32,972
Closed -$1.95M – 580
2021
Q3 		$1.95M Buy
+32,972
New +$2.59M ﹤0.01% 514

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

M&G Investment Management's FATE Position: Q4 2021 in Review

M&G Investment Management sold out of Fate Therapeutics (FATE) in Q4 2021, closing a stake of 32,972 shares — an estimated $1.95M sold.

M&G Investment Management first reported a position in FATE in Q3 2021 and held it in 1 quarter. The position peaked at $1.95M in Q3 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q4 2021.

  • M&G Investment Management reported no remaining Fate Therapeutics position as of Q4 2021 after selling out during the quarter.
  • M&G Investment Management sold 32,972 Fate Therapeutics shares in Q4 2021, an estimated $1.95M.
  • M&G Investment Management first reported a position in Fate Therapeutics in Q3 2021 and held it in 1 quarter.
  • M&G Investment Management's Fate Therapeutics position peaked at $1.95M in Q3 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2021.

Based on M&G Investment Management's 13F filing for Q4 2021, filed 18 Jan 2022.